In summary, a systematic bioinformatics analysis of DEGs demonstrated that ANXA5, STAT1, CD44, CAV1, MAPT, and ANXA2 might serve as potential biomarkers and therapeutic targets for glioma. This evidence concerns the gene MAPT and central nervous system cancer.